So, what exactly is GLP-1 microdosing, and how does it compare to traditional protocols
In order to make GLP-1 better used in the clinic, drug developers modified its structure and developed a series of GLP-1R agonists ( GLP-1, a 30- or 31-amino-acid-long peptide hormone, is a gastrointestinal peptide secreted by the intestinal tract that potentiates insulin release and reduces glucagons concentration in physiological conditions ( Scheme 1
Minamino T, Kitakaze M, Morioka T, Node K, Shinozaki Y, Chujo M, Mori H, Takeda H, Inoue M, Hori M, et al
However, the uptake is generally expected to be greater for members with higher BMIs
A systematic review ScienceDirect science/article/pii/S2214623724000048 [64] What is the pipeline for future medications for obesity
Protein then triggers satiety hormones like GLP-1, helping the body prepare for the rest of the meal